You are here:
Pharmaceutical Manufacturing — CDMO & OTC
Last Updated:February 27, 2026
About This Investor
JP-B-402
Mandate summary: From Japan, this investor is open to qualified opportunities. Their focus is: Pharmaceutical formulations (CMO/CDMO), generic formulation development and manufacturing, new drug development and manufacturing, contract manufacturing of new drugs, long – listed products, and large – scale OTC drugs Oral solid dosage forms Injectables. The stated objective is Overseas expansion of existing…
Pharmaceutical Manufacturing (CDMO)
Indonesia, Vietnam
Strategic Expansion
$6.54M - $13.1M
Majority / 100%
Request Full Investor Profile
Similar Investors
JP-B-289
Budget guidance is $6.54M – $32.7M. From Japan, they are
Healthcare (OTC / Consumer Health)
Asia, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam
Strategic Synergy
$6.54M - $32.7M
Majority (principle) | Minority (initial) possible
Food Manufacturing (Confectionery)
Malaysia, Philippines, Singapore, Thailand, Vietnam
Overseas Expansion
$654K - $19.6M
Minority / Majority / 100%
JP-B-601
They are looking for opportunities aligned with the following target
Construction
ASEAN, India
Overseas Expansion
$3.27M - $65.4M
Minority / Majority / 100% | Revenue ≥ USD 32.7M